MDMA Therapy 2026 Update: Where Things Stand After the FDA Rejection
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD in August 2024, and as of mid-2026 that decision stands. MDMA remains a Schedule I...
Psychedelic Policy USA 2026: Mid-Year Federal and State Update
Psychedelic policy in the USA is moving faster in 2026 than at any point in recent history. A federal executive order, a wave of state-level bills,...
5-MeO-DMT Therapy: What the Research Shows and Why Risks Are Real
5-MeO-DMT therapy is attracting serious interest from researchers, executives, and people seeking relief from depression, anxiety, and trauma. The compound is potent, fast-acting, and increasingly the...
Ibogaine Opioid Treatment Research: What 2025-2026 Studies Found
Ibogaine opioid treatment research has moved significantly forward in 2025 and 2026, with new clinical data, a landmark $50 million Texas state investment, and a federal...
Psychedelic Therapy Washington DC, Maryland & Virginia: 2026 Guide
Last Updated: May 2026 If you’re looking for psychedelic therapy in Washington DC, Maryland, or Virginia (DMV), your clearest option right now is ketamine, which is...
Psilocybin PTSD Therapy: What the 2026 Clinical Evidence Shows
Psilocybin PTSD therapy is no longer a fringe concept. A growing body of clinical research, including Phase 2 trials published in 2025, shows that a single...
Ready to take the next step?
Start with a complimentary conversation, or take the two-minute self-evaluation to see if this is your moment.